Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.59 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1227451 | 1.00 | S1PR1 (0.59) | S1PR1S1PR3KCNH2S1PR4S1PR5 | |
| SCHEMBL1226531 | 0.86 | S1PR1 (0.51) | S1PR1S1PR3KCNH2 | |
| SCHEMBL12385596 | 0.83 | S1PR1 (0.57) | S1PR1S1PR3KCNH2S1PR5 | |
| SCHEMBL1226795 | 0.80 | S1PR1 (0.57) | S1PR1S1PR3KCNH2 | |
| SCHEMBL2576832 | 0.76 | S1PR1 (0.75) | S1PR1S1PR3 | |
| SCHEMBL2576041 | 0.76 | S1PR1 (0.75) | S1PR1S1PR3 | |
| SCHEMBL2576829 | 0.76 | S1PR1 (0.75) | S1PR1S1PR3 | |
| SCHEMBL12288600 | 0.75 | S1PR1 (0.65) | S1PR1S1PR3KCNH2S1PR4S1PR5 | |
| SCHEMBL1227372 | 0.75 | S1PR1 (0.67) | S1PR1S1PR3KCNH2S1PR4S1PR5 | |
| SCHEMBL2565417 | 0.75 | S1PR1 (0.55) | S1PR1S1PR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462139-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2462139-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2462139-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| WO-2011017578-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011017578-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885S1PR3 2/4885KCNH2 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.